



HAL
open science

Cell-Type Specific Regulation of Cholesterologenesis by CYP46A1 Re-Expression in zQ175 HD Mouse Striatum

Katleen Pinchaud, Chloé Masson, Baptiste Dayre, Coline Mounier, Jean-François Gilles, Peter Vanhoutte, Jocelyne Caboche, Sandrine Betuing

► To cite this version:

Katleen Pinchaud, Chloé Masson, Baptiste Dayre, Coline Mounier, Jean-François Gilles, et al.. Cell-Type Specific Regulation of Cholesterologenesis by CYP46A1 Re-Expression in zQ175 HD Mouse Striatum. *International Journal of Molecular Sciences*, 2023, 24 (13), pp.11001. 10.3390/ijms241311001 . hal-04177288v2

HAL Id: hal-04177288

<https://hal.science/hal-04177288v2>

Submitted on 5 Mar 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



1 Article

2 **Cell-type specific regulation of cholesterologenesis by CYP46A1**
3 **re-expression in zQ175 HD mouse striatum**

4 **Katleen Pinchaud¹, Chloé Masson¹, Baptiste Dayre¹, Coline Mounier¹, Jean-François Gilles², Peter Vanhoutte¹,**
5 **Jocelyne Caboche¹ and Sandrine Betuing^{1*}**

6 ¹ Neuroscience Paris Seine, Institut de Biologie Paris-Seine (IBPS), CNRS UMR 8246/INSERM U1130, Sorbonne
7 Université, Paris, France

8 ² Imaging Facility, Institut de Biologie Paris-Seine (IBPS), Sorbonne Université, Paris, France

9 * Correspondence: sandrine.betuing@sorbonne-universite.fr;
10

11 **Abstract:** Cholesterol metabolism dysregulation is associated with several neurological disorders.
12 In Huntington's disease (HD), several enzymes involved in cholesterol metabolism are
13 down-regulated, among which the neuronal cholesterol 24-hydroxylase, CYP46A1, is of particular
14 interest. Restoration of CYP46A1 expression in striatal neurons of HD mouse models is beneficial
15 for motor behavior, cholesterol metabolism, transcriptomic activity and alleviates
16 neuropathological hallmarks induced by mHTT. Among the genes regulated after CYP46A1 res-
17 toration, those involved in cholesterol synthesis and efflux may explain the positive effect of
18 CYP46A1 on cholesterol precursor metabolites. Since cholesterol homeostasis results from a fi-
19 ne-tuning between neurons and astrocytes, we quantified the distribution of key genes regulating
20 cholesterol metabolism and efflux in astrocytes and neurons using *in situ* hybridization coupled
21 with S100β and NeuN immunostaining, respectively. Neuronal expression of CYP46A1 in the stri-
22 atum of HD zQ175 mice increased key cholesterol synthesis driver genes (*Hmgcr*, *Dhcr24*) specifi-
23 cally in neurons. This effect was associated with an increase of the *srebp2* transcription factor gene
24 that regulates most of the genes encoding for cholesterol enzymes. However, the cholesterol efflux
25 gene, *ApoE*, was specifically upregulated in astrocytes by CYP46A1 probably through a paracrine
26 effect. In summary, neuronal expression of CYP46A1 has a dual and specific effect on neurons and
27 astrocytes to regulate cholesterol metabolism. Neuronal restoration of CYP46A1 in HD paves the
28 way for future strategies to compensate for mHTT toxicity.

29 **Keywords:** Huntington's disease, striatum, CYP46A1, cholesterol, gene regulation, Srebp2, Hmgcr,
30 *Dhcr24*, *ApoE*, Fluorescence *in situ* Hybridization coupled with Immunostaining.

31 **Citation:** To be added by editorial staff during production.

Academic Editor: Firstname
32 Lastname

33 Received: date

34 Revised: date

35 Accepted: date

36 Published: date



37
38 **Copyright:** © 2023 by the authors,
39 Submitted for possible open access
40 publication under the terms and
41 conditions of the Creative Commons
42 Attribution (CC BY) license
43 (<https://creativecommons.org/licenses/by/4.0/>).

32 **1. Introduction**

33 Huntington's disease (HD) is a neurodegenerative disorder with autosomal dominant
34 inheritance, onset in young adults, and presents a combination of neuropsychiatric, mo-
35 tor, and cognitive symptoms [1]. The disease is caused by an abnormal expansion of CAG
36 trinucleotide repeats in the gene encoding the huntingtin protein (HTT), resulting in a
37 poly-glutamine repeat in the N-terminal region of the mutated huntingtin protein
38 (mHTT) [2]. The toxic gain of functions of mHTT and the loss of function of wild-type
39 huntingtin result in a cascade of events that leads to a progressive degeneration of me-
40 dium-sized spiny neurons (MSNs) in the striatum [3], which then extends to other brain
41 regions such as the cerebral cortex, the hypothalamus and the cerebellum. Multiple cel-
42 lular and molecular dysfunctions have been well described, including transcriptional
43 gene dysregulation, alteration of energy metabolism, synaptic transmission, BDNF syn-

thesis and transport, TrkB receptor trafficking, clearance of unfolded proteins, and alteration of cholesterol homeostasis [4].

Despite these cardinal discoveries about HD pathogenesis, a significant challenge remains to identify HD modification strategies that could be used to slow disease progression. Current therapeutic approaches focus on mHTT lowering, inhibition of mHTT aggregation and modulators of key pathways involved in HD pathogenesis such as excitotoxicity, proteostasis, mitochondrial dysfunction [5,6], and more recently cholesterol metabolism dysregulation [7,8].

The maintenance of cholesterol homeostasis is a relevant aspect of the central nervous system (CNS) functions, including for brain development, myelination, neuronal signaling and survival. Since peripheral cholesterol cannot cross the blood-brain-barrier, brain cholesterol is primarily synthesized locally by astrocytes, while the major pathway for cholesterol catabolism is achieved in neurons by the brain-specific cholesterol 24-hydroxylase enzyme (CYP46A1), leading to the conversion of cholesterol into 24 (S)-hydroxycholesterol (24S-OHC) [9]. Blood cholesterol levels are reduced in manifest HD patients [10,11], and levels of sterols upstream from cholesterol, including lanosterol, lathosterol and 7-dehydrocholesterol, are markedly decreased within the striatum of HD mice [12–17]. Additionally, 24S-OHC levels are reduced in the plasma of HD patients, paralleling caudate nucleus atrophy [11]. The mRNA level of cholesterol biosynthetic genes are reduced in HD cell lines, fibroblasts, and post-mortem striatal and cortical tissues from HD patients and in the striatum of several mouse models of HD [18–21]. In addition, we made the original observation that expression levels of CYP46A1 are strongly reduced in the putamen of HD patients and striatum of both transgenic (R6/2) and knock-in (zQ175) HD mouse models [16,17]. Restoring striatal CYP46A1 levels in neurons by gene therapy using adeno-associated virus (AAVrh10) is neuroprotective in these two HD mouse models, and this approach directly reinstates the whole cholesterol metabolism pathway, including the production of sterols (lanosterol and desmosterol) and 24S-OHC [16,17]. Strikingly, this approach ameliorated the clearance of mHTT aggregates and, most importantly, normalized the striatal transcriptome, especially for genes implicated in synaptic transmission and proteasome activity [17].

To better understand how the normalization of CYP46A1 expression reactivates cholesterol biosynthesis, it remains to be determined whether CYP46A1 regulation of cholesterol biosynthetic genes occurs in astrocytes and/or MSNs, the main neuronal population of the striatum. Two non-exclusive hypotheses can be proposed: i) neuronal expression of CYP46A1 induced a paracrine effect on astrocyte cholesterol biosynthesis through secretion of 24S-OHC product, which is an activator of nuclear Liver X Receptor (LXR) or, ii) neuronal expression of CYP46A1 could act locally in neurons to activate cholesterol biosynthesis [22]. To address this question, we took advantages of fluorescent *in situ* hybridization (FISH) coupled with immunostaining to quantify key cholesterol genes in astrocytes and MSNs of HD mice. We found that neuronal expression of CYP46A1 in HD zQ175 mice has a local effect on MSNs for the two cholesterol gene drivers, *ie Hmgcr* and *Dhcr24*, and a paracrine effect on astrocytes for *ApoE* cholesterol efflux gene. On the other hand, the sterol regulatory element binding protein 2 (SREBP2) transcription factor was regulated in both MSNs and astrocytes after CYP46A1 expression in MSNs. Altogether, these results suggest a bimodal effect of CYP46A1: one in MSNs to reinstate cholesterol biosynthesis and one in astrocytes to favor cholesterol efflux. The beneficial effect of CYP46A1 in HD reflects the dynamic balance between cholesterol synthesis, uptake, and export, all integrated into a dialogue between MSNs and astrocytes.

2. Results

2.1 Validation of virus-mediated expression of GFP and CYP46A1-HA in dorsal striatum and validation of FISH analysis coupled with cell-specific immunolabeling

2.1.1 Expression of CYP46A1 in the striatum of HD mice

In order to study the regulation of genes involved in cholesterol metabolism in HD mice after virus-driven CYP46A1 expression, bilateral stereotaxic injection of AAVrh10-GFP (control) and AAVrh10-CYP46A1-HA (a human version of CYP46A1 with a haemagglutinin (HA) tag) was performed in the striatum of four-month old mice. Five months later, FISH was performed to quantify gene expression in neurons (NeuN immunolabelling) and astrocytes (S100 β immunolabelling) (Figure 1.A). We first examined the cell transduction of these two AAVs. As shown in Figure 1.B, GFP and CYP46A1-HA expression were strongly expressed in the dorsal striatum five months after stereotaxic injection as previously described [16,17]. Importantly, double labeling of HA and a neuronal marker (NeuN) showed that the majority of striatal cells expressing CYP46A1-HA were neurons (92.8%, data not shown) (Figure 1.A, right panels). Therefore, the experimental setup allows a long-lasting neuronal expression of CYP46A1 in the striatum of zQ175 mice.




Figure 1. Validation of striatal expression of CYP46A1 in mice.

(A) Experimental set up to assess mRNA quantification on brain sections within neurons and astrocytes. Created with BioRender.com (B) Left and middle panels: expression of GFP in WT (WT-GFP) and HD (HD-GFP) mice after stereotaxic injection of AAV-GFP. Right panels: expression of CYP46A1-HA revealed by HA immunostaining in HD (HD-CYP46A1) mice after stereotaxic injection of AAV-CYP46A1-HA on striatal sections (Scale bar: 100 μ m). A close-up of CYP46A1-HA in HD is shown after double HA/NeuN immunostaining (scale bar: 30 μ m) and reveals neuronal tropism of AAVrh10. CC: corpus callosum, LV: Lateral Ventricle, D.ST: Dorsal Striatum

2.1.2 Imaging tools to quantify mRNA signals after FISH coupled with IHC

We next sought to visualize specific mRNAs related to cholesterol metabolism in striatal neurons and astrocytes to analyze the effect of CYP46A1-mediated gene regulation in each cell population in HD mice. FISH was performed on 30- μ m-thick mouse brain sections, using specific fluorophore-coupled RNAscope[®] probes against *Hmgcr*, *Dhcr24*, *Srebp2*, and *ApoE*. Since each FISH signal gave rise to different patterns, with either sparse or densely packed puncta, a 2D projection (maximum intensity) followed by intensity thresholding (Otsu method) allowed to measure the number of dots in each

nucleus (identified manually by ROIs) with the immunostaining signal (NeuN immunolabeling for neurons and S100 β immunolabeling for astrocytes). For *Srebp2* (Figure 2.A) and *Dhcr24* (see Figure 4), we used the machine-learning Advanced Weka Segmentation plugin on 2D projection to perform image segmentation based on pixel classification and separate all dots. Then, a threshold and a particle analysis allow us to determine the number of dots in each DAPI-NeuN (Figure 2.A) or DAPI-S100 β (Figure 2.B) labeling. For *ApoE*, which retrieved very dense signal, we used macros in ImageJ to count the dot signal encapsulated in the nucleus in 3D. Due to the heterogeneity of the DAPI and immunostaining signals, we used the deep learning-based plugin Stardist [23] with fine-tuning training on the model with a small amount of our images for a better segmentation result. Then, cells are manually selected for counting the dot signals in neurons (Figure 2.C) or astrocytes (Figure 2.D) was performed after a difference of Gaussian filtering then a 3D Dot Segmentation [24]. Counting was performed with 3D ROI Manager plugin from the 3D ImageJ Suite [25].




Figure 2. Imaging methods after FISH coupled with IHC.

(A) Sequence of the different stages for *Srebp2* signal quantification in neurons (NeuN immunostaining in red) and (B) in astrocytes (S100 β immunostaining in red): contouring of nucleus labeled with DAPI (in white) from positive immunostained cells, mask application to the *Srebp2* signal and segmentation result. (C) Stages of macro for *ApoE* signal quantification in neurons (NeuN immunostaining in red), and (D) astrocytes (S100 β immunostaining in red): NeuN/S100 β -DAPI labeling, *ApoE* signal before macro treatment, mask and Gaussian result (after macro). Scale bar: 17 μ m.

2.2 Analysis of *Hmgcr* and *Dhcr24*, two key cholesterol synthesis genes, in neurons and astrocytes after CYP46A1-HA expression in HD mice

The effect of CYP46A1 in the cholesterologenic pathway was then studied on two critical genes coding the rate-limiting enzyme HMGCR and a key node enzyme DHCR24, which ensures the link between the Kandutch-Russel and Bloch pathways [7]. *Hmgcr* mRNA FISH signals were detected as discrete dots in the nucleus (Figure 3.A). Quantification of *Hmgcr* puncta in neurons (NeuN staining) and astrocytes (S100 β staining) did not show any difference between WT-GFP and HD-GFP mice in both cell populations. These results confirm previous studies showing no major dysregulation of *Hmgcr* mRNA expression in the striatum of zQ175 at 12 months [17]. However, CYP46A1 re-expression after

AAVrh10-CYP46A1-HA transduction induced a significant increase of *Hmgcr* expression in neurons (Figure 3.A-B) but not in astrocytes (Figure 3.D-E). MSNs, which comprise around 90 % of the neurons in the striatum, belong to two anatomically and functionally distinct populations that exert opposite role in the selection of motor plans. MSNs of the direct pathway (D1 MSNs) express dopaminergic receptor type 1 (DRD1), while those of the indirect pathway (D2 MSNs) express dopaminergic receptor type 2 (DRD2) [26]. D1 and D2 MSNs exhibit distinctive structural and functional properties in zQ175 mice [27–29]. Hence, we sought to analyze if CYP46A1-mediated increase of *Hmgcr* was more prominent in one of the two MSNs populations. We took advantage of the multiplex ability of RNAscope®, to analyze the expression of *Hmgcr* in both D1 and D2 MSNs populations of HD mice injected with AAVrh10-CYP46A1-HA. As expected, *Drd1* and *Drd2* dots were perfectly segregated in dorsal striatum sections from HD mice (Fig 3.C). In HD-CYP46A1 mice, *Hmgcr* mRNA levels are equally distributed in both D1 and D2 MSNs populations (53% in D1 MSNs and 46.9% in D2 MSNs and) (Fig 3.C).




Figure 3. *Hmgcr* gene expression in neurons and astrocytes after CYP46A1-HA expression in HD mice.

(A) Mice were injected with AAVrh10-GFP (WT GFP and HD GFP) or AAVrh10-CYP46A1-HA (HD-CYP46A1). RNAscope® coupled with NeuN immunostaining was performed on WT and HD brain mouse sections and images were taken at 63x objective (Scale bar = 17 μm). (B) Quantification of dots on approximately 400 neurons * p < 0.05 (HD-GFP vs HD-CYP46A1). (C) RNAscope® discrimination between neurons expressing *Drd1* and *Drd2* in the HD-CYP46A1 group and proportion

164
165
166
167
168
169
170
171
172
173
174
175
176
177
178


179
180
181
182
183
184
185
186

187
188
189
190
191
192
193
194
195
196
197
198

of *Hmgcr* in each D1 or D2 MSNs in this same group. (D) RNAscope® coupled with S100 β immunostaining (Scale bar = 17 μ m). (E) Quantification of dots on approximately 100 astrocytes. Results are expressed as mean \pm SEM (n = 3–4). One-way ANOVA with Kruskal-Wallis post-hoc test was used for statistical analysis.

With regard to *Dhcr24* mRNA levels, we did not detect differences in either neurons or astrocytes from WT-GFP and HD-GFP mice. (Figure 4.A-D), while CYP46A1 re-expression induced an increase of *Dhcr24* levels in neurons (Figure 4.B) but not astrocytes (Figure 4.D).

Altogether, these results show that neuronal CYP46A1 expression has a direct effect on cholesterogenic enzymes within the two MSNs populations and no action on astrocytes.



199
200
201
202
203
204
205
206
207
208
209
210
211
212
213

Figure 4. *Dhcr24* gene expression in neurons and astrocytes after CYP46A1-HA expression in HD mice.

(A) Mice were injected with AAVrh10-GFP (WT-GFP and HD-GFP) or AAVrh10-CYP46A1-HA (HD-CYP46A1). RNAscope® coupled with NeuN immunostaining was performed on WT and HD brain mouse sections and images were taken at 63x objective (Scale bar = 17 μ m). (B) Quantification of dots on approximately 400 neurons ***p < 0.0001 (WT-GFP vs HD-CYP46A1) and ***p < 0.001 (HD-GFP vs HD-CYP46A1). (C) RNAscope® coupled with S100 β immunostaining (Scale bar = 17 μ m). (D) Quantification of dots on approximately 100 astrocytes. Results are expressed as mean \pm SEM (n = 3–4). One-way ANOVA with Kruskal-Wallis post-hoc test was used for statistical analysis.

2.3 Regulation of *Srebp2* transcription factor gene in neurons and astrocytes after CYP46A1-HA expression in HD mice

Cholesterol biosynthesis is regulated by the transcription factor SREBP2, which activates the expression of most cholesterol biosynthesis genes [30]. The nuclear level and activity of the N-terminal active fragment of SREBP2 are reduced in HD cellular models and mouse brains, and *Srebp2* gene therapy in striatal astrocytes alleviates HD phenotypes in R6/2 mice [31]. We previously showed that the *Srebp2* mRNA level is significantly decreased in zQ175 mice and CYP46A1 expression tended to restore the proportion of nuclear SREBP2 activity in the striatum of zQ175 [17]. We quantified *Srebp2* mRNA in MSNs and astrocytes to better characterize CYP46A1 beneficial effect on cholesterologenesis (Figure 5). *Srebp2* mRNA quantification did not show any differences between WT-GFP and HD-GFP groups in either neuronal cells (Figure 5.A-B) or astrocytes (Figure 5.D-E), however, CYP46A1 significantly increased *Srebp2* mRNA expression in neurons and astrocytes in HD striatum (Figure 5.B; 5.E). The level of *Srebp2* mRNA in HD-CYP46A1 was equally distributed in both D1 and D2 MSNs of HD mice (50.31% and 49.69%, respectively) (Figure 5.C). Overall, neuronal CYP46A1 expression in HD mice has a direct role on neurons and a paracrine effect in astrocytes to regulate *Srebp2* gene expression.




Figure 5. *Srebp2* gene expression in neurons and astrocytes after CYP46A1-HA expression in HD mice.

(A) Mice were injected with AAVrh10-GFP (WT-GFP and HD-GFP) or AAVrh10-CYP46A1-HA (HD-CYP46A1). RNAscope® coupled with NeuN immunostaining was performed on WT and HD brain mouse sections and images were taken at 63x objective (Scale bar = 17 μm). (B) The number of

214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230

231
232
233
234
235
236

dots in neurons was quantified on approximately 400 neurons *** $p < 0.001$ (WT-GFP vs HD-CYP46A1) and ** $p < 0.005$ (HD-GFP vs HD-CYP46A1). (C) RNAscope® discrimination between neurons expressing *Drd1* or *Drd2* in HD-CYP46A1 group and proportion of *Srebp2* in each D1 or D2 MSN in this same group. (D) RNAscope® coupled with S100 β immunostaining (Scale bar = 17 μ m). (E) Quantification of dots on approximately 100 astrocytes. Results are expressed as mean \pm SEM (n = 3–4). One-way ANOVA with Kruskal-Wallis post-hoc test was used for statistical analysis.

2.4 Neuronal CYP46A1 expression effect on *ApoE* cholesterol efflux gene

APOE protein is mainly expressed by glial cells including astrocytes, microglia, and oligodendrocytes and is involved in pathogenesis of neurodegenerative diseases [32]. Cholesterol transport by astrocytes to neurons is less efficient in HD, with decreased expression of *ApoE* mRNAs, and less release of APOE by astrocytes expressing mHTT [21,33]. Since CYP46A1 restores *ApoE* mRNA expression in the striatum of zQ175 mice [17], we quantified its expression in neurons and astrocytes. We focused on nuclear *ApoE* mRNA to quantify neo-synthesized transcripts (Figure 6.A; 6.C). *ApoE* mRNA dots quantification did not show difference in MSNs between WT-GFP, HD-GFP and HD-CYP46A1 mice (Figure 6.B). However, and as expected, *ApoE* dots were significantly lower in astrocytes of HD-GFP mice as compared to WT-GFP mice (Figure 6.D). Moreover, CYP46A1 restored *ApoE* mRNA expression in astrocytes of HD (Figure 6.D).




Figure 6. *ApoE* gene expression in neurons and astrocytes after CYP46A1-HA expression in HD mice.

(A) Mice were injected with AAVrh10-GFP (WT-GFP and HD-GFP) or AAVrh10-CYP46A1-HA (HD-CYP46A1). RNAscope® coupled with NeuN immunostaining was performed on WT and HD brain mouse sections and images were taken at 63x objective (Scale bar = 17 μ m). (B) Quantification of dots on approximately 400 neurons. (C) RNAscope® coupled with S100 β immunostaining (Scale bar = 17 μ m). (D) Quantification of dots on approximately 100 astrocytes ** $p < 0.05$ (WT-GFP vs

237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255

256
257
258
259
260
261
262
263

264 HD-GFP and HD-GFP *vs* HD-CYP46A1). Results are expressed as mean \pm SEM (n = 3–4). One-way
265 ANOVA with Kruskal-Wallis post-hoc test was used for statistical analysis.

267 3. Discussion

268 Cholesterol metabolism dysregulation plays a critical role in HD pathogenesis and
269 recent studies highlight the interest of considering this pathway as a therapeutic target
270 [7,34]. The neuronal enriched enzyme CYP46A1 is down-regulated in HD transgenic and
271 knock-in mouse models and its striatal restoration alleviates HD phenotypes [16,17]. In
272 particular, CYP46A1 reinstates cholesterol synthesis, cholesterol efflux and catabolism. We
273 developed a co-labeling method that combined mRNA *in situ* hybridization and immu-
274 nofluorescence detection of MSNs and astrocytes on brain sections to assess
275 CYP46A1-mediated regulation of cholesterol pathway genes in these two cellular popu-
276 lations. We found that CYP46A1 exerts a bimodal effect on cholesterol metabolism, one in
277 neuronal cells (MSNs) on key cholesterol synthesis genes, and one in astrocytes, likely *via*
278 paracrine effects on cholesterol transport/efflux.

279 Characterization of mRNA distribution in different cell types such as neurons or
280 astrocytes, is now possible on a single brain slice. However, the combination of
281 RNAscope® and immunostaining impairs immunolabelling quality probably due to
282 protease digestion treatment. NeuN and S100 β immunodetection associated with
283 RNAscope® has been developed but as mentioned by other studies [31,17], technical im-
284 provements are still necessary, especially for the NeuN immunostaining signal. Addi-
285 tionally, we were unable to compare the dot quantification of mRNA between both cell
286 types, probably because each immunostaining affects FISH signals differently.
287 RNAscope® provides the advantages of *in situ* analysis of mRNA with a single-molecule
288 visualization [35], but in case of abundant mRNA (e.g. *ApoE* mRNA), the dots cannot be
289 differentiated and quantification required the use of macros in ImageJ.

290 In our previous study, we showed that CYP46A1 restoration had a strong impact on
291 cholesterol metabolism by increasing 24S-OHC, the product of cholesterol degradation
292 but also cholesterol precursor levels [17]. In the adult brain, cholesterol is mainly syn-
293 thesized by astrocytes [7]; however, depending on the brain physiopathogenesis, one
294 cannot exclude that a re-activation of cholesterol synthesis may occur in neurons. Indeed,
295 in co-cultures of neurons and astrocytes, neurons can synthesize cholesterol, but at a
296 lower rate as compared to astrocytes, probably because of the high energy cost of this
297 metabolic pathway [32]. In HD mouse models, transcriptomic studies on sorted neurons
298 and astrocytes highlight a cell-intrinsic pathology across mouse models of HD [36–38].
299 However, results may differ depending on HD mouse models (R6/2 transgenic which
300 express N-terminal part of mHTT *versus* zQ175 knock-in mice expressing the full length
301 mHTT). For the R6/2 mice-derived-astrocytes, the most altered pathways are related to
302 fatty acid and cholesterol metabolism whereas opioid signaling, calcium signaling, and
303 synaptogenesis are the core altered pathways in neurons [37,38]. In zQ175, astrocytes do
304 not show down-regulation of cholesterol synthesis genes which reveals transcriptomic dif-
305 ferences between glia expressing truncated mHTT *versus* full-length mHTT [37]. Our
306 results are consistent with these studies as none of the 3 cholesterol synthesis key mRNAs
307 tested (*Hmgcr*, *Dhcr24*, and *Srebp2*) are down-regulated in zQ175 astrocytes. The
308 downregulation of *ApoE* mRNA that we observed in zQ175 astrocytes corroborates pre-
309 vious results seen in cultures of HD astrocytes [21,33].

310 Our study suggests that the neuronal enzyme CYP46A1 is able to reinstate choles-
311 terol metabolism specifically and locally in neurons with an upregulation of *Hmgcr*,
312 *Dhcr24* mRNA. This effect could be due to SREBP2, the key transcription factor regulat-
313 ing cholesterol synthesis, which is upregulated in HD neurons expressing CYP46A1. We can
314 therefore exclude a possible contribution of astrocytes in CYP46A1-mediated increase of
315 cholesterol metabolism. However, we propose that 24S-OHC produced by CYP46A1 in
316 neurons may increase *ApoE* mRNA expression in astrocytes through a paracrine effect.
317 Indeed, 24S-OHC is a ligand of LXR positively regulating transcription of *ApoE* [22] that

318 encodes cargo proteins for cholesterol transport from astrocytes to neurons [39,40].
319 Therefore, both cell populations need to be considered in the CYP46A1-mediated bene-
320 ficial effect in HD mice.

321 The coupling of FISH with immunostaining can therefore be used to study the dis-
322 tribution of mRNAs in astrocytes and neurons in HD brain sections. CYP46A1 increases
323 cholesterol synthesis in neurons and cholesterol efflux on astrocytes probably through a
324 paracrine effect. This study focused on neurons and astrocytes could be extended to other
325 cell types involved in HD physiopathology such as microglia and oligodendrocytes.

326 4. Materials and Methods

327 4.1 Mice

328 Four-month-old littermate WT or heterozygous zQ175 mice were used. zQ175 mice
329 (B6J.129S1-Htttm1Mfc/190Chd1j) were obtained from Jackson Laboratories. All mice used
330 in the study were from the first or second offspring, and the genotype was determined by
331 polymerase chain reaction (PCR) using genomic DNA extracted from the tail or ear. Both
332 males and females were housed in groups with a 12-h light/ dark cycle, provided with
333 food and water ad libitum, and kept at a constant temperature (19-22 °C) and humidity
334 (40-50%). All experiments performed on animals followed the European Community
335 guidelines (2010/63/EU) and the French Directive for animal experimentation (2013/118)
336 for the use and care of experimental animals and the requirements for the three Rs for
337 Animal Welfare. The ethics committee and approved by the French Ministry of Research
338 (#17424) approved the animal study protocol.

339 4.2 Production and stereotaxic injection of AAVrh10.GFP and AAVrh10.CYP46A1.HA

340 All AdenoAssociatedVirus (AAV) vectors were obtained by Atlantic Gene therapies (In-
341 term U1089, Nantes, France). The viral constructs for AAVrh10-GFP and
342 AAVrh10-CYP46A1-HA contain the expression cassette consisting of either the GFP or
343 the human CYP46A1, driven by a CMV/ β -actin hybrid promoter (CAG) surrounded by
344 inverted terminal repeats of AAVrh10. The stereotaxic coordinates were: 1 mm rostral to
345 the bregma, 2 mm lateral to the midline and 3.25 mm ventral to the skull surface. The rate
346 of injection was 0.2 μ l/min with a total volume of 2 μ l per striatum (equivalent to 3.10⁹
347 genomic particles).

348 4.3 Brain section preparation

349 Five months after stereotaxic injections, mice were deeply anesthetized by intraperitoneal
350 injection of euthazol (150 mg/kg). Intracardiac perfusion of 4% paraformaldehyde in 0.1
351 M Na₂HPO₄/NaH₂PO₄ buffer, pH 7.5 was performed, and brains were stored overnight
352 in the same solution at 4°C. Then, brains were transferred to a cryoprotective solution
353 containing 30 % sucrose and store at -20°C. Coronal brain sections (30 μ m) were per-
354 formed using a cryostat (Leica®) and sections were stored at -20 °C in glycerol and eth-
355 ylene glycol phosphate buffer.

356 4.4 Immunostaining

357 Brain sections were incubated with primary antibodies overnight at 4°C: mouse-anti
358 NeuN (1:500; Millipore); rat anti-HA (hemagglutinin) (1:400; Roche). Secondary anti-
359 bodies (anti-mouse Cy3 (1:500; Merck), anti-rat Alexa Fluor 488 (1:500; ThermoFischer),
360 were incubated in 5% NGS (Normal Goat Serum) in Phosphate Buffer Saline (PBS) for 2h
361 at room temperature (RT). Sections were then labelled with Hoechst solution to stain
362 nuclei and mounted under coverslips in Prolong Gold Antifade reagent (Invitrogen).

4.5 FISH coupled with Immunostaining

Transduced regions were systematically visualized by either GFP fluorescence or HA immunostaining (expression of CYP46A1) to select sections for FISH assay. FISH was performed using specific fluorophore-coupled RNAscope® probes against *Hmgcr*, *Dhcr24*, *Srebp2* and *ApoE*. RNAscope® was coupled with immunocytochemistry according to manufacturer's protocol of RNAscope® Multiplex Fluorescent Reagent Kit v2 (Bio-Techne). Brain sections were first incubated in hydrogen peroxide (H₂O₂) (BioTechne) for 10 min at RT. The sections were washed in Tris-buffered saline (TBS) with Tween® (50 mM Tris-Cl, pH 7.6; 150 mM NaCl; 0.1% Tween® 20) at RT, and mounted on Super Frost®-treated glass slides. Then, sections were dried twice for 1h at RT (with a quick immersion in deionized water in between), incubated for 1 h at 60°C in a dry oven, and dried again overnight at RT in the dark. After rapid immersion in deionized water at RT for rehydration, the excess of liquid was removed with absorbing paper (repeated at each step) and a hydrophobic barrier was drawn. A rapid immersion in pure ethanol was performed and slides were incubated at 100°C in a steamer with a drop of RNAscope® Target Retrieval Reagent (BioTechne) for 15 min. After three washes in deionized water at RT, a last wash of TBS-Tween® was performed. Sections were then incubated overnight with primary antibodies: mouse-anti NeuN (1:500; Millipore) in a Co-detection antibody diluent (BioTechne) or rabbit anti-S100β (ready to use; Dako) at 4°C. Brain sections were post-fixed with cold PFA-PBS for 30 min at RT, followed by treatment with RNAscope® Protease Plus (BioTechne) for 30 min at 40°C in a humid box (to unmask the mRNAs). After three washes in deionized water, brain sections were incubated with hybridization probes of interest (2h at 40°C in a humid box) followed by amplification (30 and 15 min at 40°C) and revelation of RNAscope® signals with Opals at different wavelengths: Opal520, Opal 620 and Opal 650 (30 min at 40°C; 1:1500 to 1:3000 depending on the RNAscope® probes; Akoya Biosciences) with washes between each step. Finally, the last immunofluorescence step was performed by incubating the secondary antibodies with Co-detection antibody diluent (BioTechne) for 30 min at RT: anti-mouse Cy3 (1:500; Merck), anti-rabbit Cy3 (1:500; Merck). Sections were then incubated with DAPI solution to stain nuclei and mounted under coverslips in Mowiol (Sigma Aldrich).

4.5 Image acquisition and analysis

Image stacks were taken using a confocal laser-scanning microscope (SP5, Leica Microsystems), with a pinhole aperture set to 1 Airy unit. Stack of confocal images were done using a x10 and x40 objectives (tropism and neuronal transduction analysis) or a x63 oil objective (RNA detection microscopy analysis), with a 0.3 μm z-interval. Laser intensity and detector gain were constant for all images of the same analysis. The number of nuclear dots in neurons and astrocytes was quantified in the AAV-transduced sections using imaging tools described in the result session (Figure 2). Then, the average number of RNAscope® dots per cell was quantified by dividing the total number of dots obtained in all selected cells by the number of neurons or astrocytes analyzed. For each condition, around 400 neurons and 100 astrocytes were analyzed. For each analysis, 3 to 4 mice were used (3 for WT-GFP group, 4 for HD-GFP group and 4 for HD-CYP46A1 group) for a total of 400 neurons and 100 astrocytes analyzed in each condition.

4.6 Statistical analysis

Statistical analysis was performed with GraphPad Prism 6 software. All data are represented as mean ±SEM. Statistical significance for RNA dots quantification was evaluated using a one-way ANOVA followed by Kruskal-Wallis *post hoc* test.

Author Contributions: For research articles with several authors, a short paragraph specifying their individual contributions must be provided. The following statements should be used “Conceptualization, S.B., J.C and K.P.; methodology, S.B ,K.P, C.M, J.F.G, P.V and J.C and; formal analysis, S.B,K.P, J.F.G, C.M and B.D.; writing—original draft preparation, S.B and K.P.; writing—review and editing, S.B, K.P, C.M, C.M, B.D, J.C and P.V; funding acquisition, S.B. All authors have read and agreed to the published version of the manuscript.” Please turn to the [CRediT taxonomy](#) for the term explanation. Authorship must be limited to those who have contributed substantially to the work reported.

Funding: “This research was funded by AFM-Telethon, grant number 22986”, “Agence Nationale de la Recherche ANR AAPG 2020, STERO-HD, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, and Sorbonne Université Faculté des Sciences et Ingénierie. Image acquisition was performed at the IBPS Imaging Facility. The IBPS Imaging facility is supported by Region-Île-de-France, Sorbonne-University and CNRS

Institutional Review Board Statement: The animal study protocol was approved by the Charles Darwin N°5 Ethics Committee, Paris (protocol code APAFIS#1724-2018110517162996 and date of approval: November 2019)”

Informed Consent Statement: “Not applicable.”

Data Availability Statement: Data available upon request from the authors.

Acknowledgments: We thank Martine Cohen-Salmon and Leila Slaoui for their fruitful scientific advices on RNAscope methodology. We thank Nicolas Heck for his careful proofreading of the manuscript and his invaluable advice.

Conflicts of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Aylward, E.H.; Codori, A.M.; Rosenblatt, A.; Sherr, M.; Brandt, J.; Stine, O.C.; Barta, P.E.; Pearlson, G.D.; Ross, C.A. Rate of Caudate Atrophy in Presymptomatic and Symptomatic Stages of Huntington’s Disease. *Mov Disord* **2000**, *15*, 552–560, doi:10.1002/1531-8257(200005)15:3<552::AID-MDS1020>3.0.CO;2-P.
2. A Novel Gene Containing a Trinucleotide Repeat That Is Expanded and Unstable on Huntington’s Disease Chromosomes. The Huntington’s Disease Collaborative Research Group. *Cell* **1993**, *72*, 971–983, doi:10.1016/0092-8674(93)90585-e.
3. Saudou, F.; Humbert, S. The Biology of Huntingtin. *Neuron* **2016**, *89*, 910–926, doi:10.1016/j.neuron.2016.02.003.
4. Tabrizi, S.J.; Flower, M.D.; Ross, C.A.; Wild, E.J. Huntington Disease: New Insights into Molecular Pathogenesis and Therapeutic Opportunities. *Nat Rev Neurol* **2020**, *16*, 529–546, doi:10.1038/s41582-020-0389-4.
5. Duan, W.; Urani, E.; Mattson, M.P. The Potential of Gene Editing for Huntington’s Disease. *Trends Neurosci* **2023**, *46*, 365–376, doi:10.1016/j.tins.2023.02.005.
6. Tabrizi, S.J.; Estevez-Fraga, C.; van Roon-Mom, W.M.C.; Flower, M.D.; Scahill, R.I.; Wild, E.J.; Muñoz-Sanjuan, I.; Sampaio, C.; Rosser, A.E.; Leavitt, B.R. Potential Disease-Modifying Therapies for Huntington’s Disease: Lessons Learned and Future Opportunities. *Lancet Neurol* **2022**, *21*, 645–658, doi:10.1016/S1474-4422(22)00121-1.
7. Kacher, R.; Mounier, C.; Caboche, J.; Betuing, S. Altered Cholesterol Homeostasis in Huntington’s Disease. *Front Aging Neurosci* **2022**, *14*, 797220, doi:10.3389/fnagi.2022.797220.
8. Valenza, M.; Cattaneo, E. Emerging Roles for Cholesterol in Huntington’s Disease. *Trends Neurosci* **2011**, *34*, 474–486, doi:10.1016/j.tins.2011.06.005.
9. Lund, E.G.; Guileyardo, J.M.; Russell, D.W. cDNA Cloning of Cholesterol 24-Hydroxylase, a Mediator of Cholesterol Homeostasis in the Brain. *Proc Natl Acad Sci U S A* **1999**, *96*, 7238–7243, doi:10.1073/pnas.96.13.7238.
10. Leoni, V.; Mariotti, C.; Tabrizi, S.J.; Valenza, M.; Wild, E.J.; Henley, S.M.D.; Hobbs, N.Z.; Mandelli, M.L.; Grisoli, M.; Björkhem, I.; et al. Plasma 24S-Hydroxycholesterol and Caudate MRI in Pre-Manifest and Early Huntington’s Disease. *Brain* **2008**, *131*, 2851–2859, doi:10.1093/brain/awn212.

- 458 11. Leoni, V.; Long, J.D.; Mills, J.A.; Di Donato, S.; Paulsen, J.S.; PREDICT-HD study group Plasma
459 24S-Hydroxycholesterol Correlation with Markers of Huntington Disease Progression. *Neurobiol Dis* **2013**, *55*,
460 37–43, doi:10.1016/j.nbd.2013.03.013.
- 461 12. Valenza, M.; Leoni, V.; Tarditi, A.; Mariotti, C.; Björkhem, I.; Di Donato, S.; Cattaneo, E. Progressive Dysfunction
462 of the Cholesterol Biosynthesis Pathway in the R6/2 Mouse Model of Huntington’s Disease. *Neurobiology of Disease*
463 **2007**, *28*, 133–142, doi:10.1016/j.nbd.2007.07.004.
- 464 13. Valenza, M.; Carroll, J.B.; Leoni, V.; Bertram, L.N.; Björkhem, I.; Singaraja, R.R.; Di Donato, S.; Lutjohann, D.;
465 Hayden, M.R.; Cattaneo, E. Cholesterol Biosynthesis Pathway Is Disturbed in YAC128 Mice and Is Modulated by
466 Huntingtin Mutation. *Hum Mol Genet* **2007**, *16*, 2187–2198, doi:10.1093/hmg/ddm170.
- 467 14. Leoni, V.; Mariotti, C.; Nanetti, L.; Salvatore, E.; Squitieri, F.; Bentivoglio, A.R.; Bandettini di Poggio, M.;
468 Bandettini Del Poggio, M.; Piacentini, S.; Monza, D.; et al. Whole Body Cholesterol Metabolism Is Impaired in
469 Huntington’s Disease. *Neurosci Lett* **2011**, *494*, 245–249, doi:10.1016/j.neulet.2011.03.025.
- 470 15. Kreilaus, F.; Spiro, A.S.; Hannan, A.J.; Garner, B.; Jenner, A.M. Brain Cholesterol Synthesis and Metabolism Is
471 Progressively Disturbed in the R6/1 Mouse Model of Huntington’s Disease: A Targeted GC-MS/MS Sterol
472 Analysis. *J Huntingtons Dis* **2015**, *4*, 305–318, doi:10.3233/JHD-150170.
- 473 16. Boussicault, L.; Alves, S.; Lamazière, A.; Planques, A.; Heck, N.; Mounné, L.; Despres, G.; Bolte, S.; Hu, A.; Pagès,
474 C.; et al. CYP46A1, the Rate-Limiting Enzyme for Cholesterol Degradation, Is Neuroprotective in Huntington’s
475 Disease. *Brain* **2016**, *139*, 953–970, doi:10.1093/brain/awv384.
- 476 17. Kacher, R.; Lamazière, A.; Heck, N.; Kappes, V.; Mounier, C.; Despres, G.; Dembitskaya, Y.; Perrin, E.; Christaller,
477 W.; Sasidharan Nair, S.; et al. CYP46A1 Gene Therapy Deciphers the Role of Brain Cholesterol Metabolism in
478 Huntington’s Disease. *Brain* **2019**, *142*, 2432–2450, doi:10.1093/brain/awz174.
- 479 18. Sipione, S.; Rigamonti, D.; Valenza, M.; Zuccato, C.; Conti, L.; Pritchard, J.; Kooperberg, C.; Olson, J.M.; Cattaneo,
480 E. Early Transcriptional Profiles in Huntingtin-Inducible Striatal Cells by Microarray Analyses. *Hum Mol Genet*
481 **2002**, *11*, 1953–1965, doi:10.1093/hmg/11.17.1953.
- 482 19. Valenza, M.; Rigamonti, D.; Goffredo, D.; Zuccato, C.; Fenu, S.; Jamot, L.; Strand, A.; Tarditi, A.; Woodman, B.;
483 Racchi, M.; et al. Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington’s Disease. *J. Neurosci.* **2005**,
484 *25*, 9932–9939, doi:10.1523/JNEUROSCI.3355-05.2005.
- 485 20. Samara, A.; Galbiati, M.; Luciani, P.; Deledda, C.; Messi, E.; Peri, A.; Maggi, R. Altered Expression of
486 3-Betahydroxysterol Delta-24-Reductase/Selective Alzheimer’s Disease Indicator-1 Gene in Huntington’s Disease
487 Models. *J Endocrinol Invest* **2014**, *37*, 729–737, doi:10.1007/s40618-014-0098-1.
- 488 21. Valenza, M.; Marullo, M.; Di Paolo, E.; Cesana, E.; Zuccato, C.; Biella, G.; Cattaneo, E. Disruption of
489 Astrocyte-Neuron Cholesterol Cross Talk Affects Neuronal Function in Huntington’s Disease. *Cell Death Differ*
490 **2015**, *22*, 690–702, doi:10.1038/cdd.2014.162.
- 491 22. Abildayeva, K.; Jansen, P.J.; Hirsch-Reinshagen, V.; Bloks, V.W.; Bakker, A.H.F.; Ramaekers, F.C.S.; de Vente, J.;
492 Groen, A.K.; Wellington, C.L.; Kuipers, F.; et al. 24(S)-Hydroxycholesterol Participates in a Liver X
493 Receptor-Controlled Pathway in Astrocytes That Regulates Apolipoprotein E-Mediated Cholesterol Efflux. *J Biol*
494 *Chem* **2006**, *281*, 12799–12808, doi:10.1074/jbc.M601019200.
- 495 23. Frangi, A.F.; Schnabel, J.A.; Davatzikos, C.; Alberola-López, C.; Fichtinger, G. *Medical Image Computing and*
496 *Computer Assisted Intervention–MICCAI 2018: 21st International Conference, Granada, Spain, September 16–20, 2018,*
497 *Proceedings, Part IV*; Springer, 2018; Vol. 11073;.

- 498 24. Heck, N.; Dos Santos, M.; Amairi, B.; Sallery, M.; Besnard, A.; Herzog, E.; Boudier, T.; Vanhoutte, P.; Caboche, J. A
499 New Automated 3D Detection of Synaptic Contacts Reveals the Formation of Cortico-Striatal Synapses upon
500 Cocaine Treatment in Vivo. *Brain Struct Funct* **2015**, *220*, 2953–2966, doi:10.1007/s00429-014-0837-2.
- 501 25. Ollion, J.; Cochenec, J.; Loll, F.; Escudé, C.; Boudier, T. TANGO: A Generic Tool for High-Throughput 3D Image
502 Analysis for Studying Nuclear Organization. *Bioinformatics* **2013**, *29*, 1840–1841, doi:10.1093/bioinformatics/btt276.
- 503 26. Surmeier, D.J.; Song, W.J.; Yan, Z. Coordinated Expression of Dopamine Receptors in Neostriatal Medium Spiny
504 Neurons. *J Neurosci* **1996**, *16*, 6579–6591, doi:10.1523/JNEUROSCI.16-20-06579.1996.
- 505 27. Goodliffe, J.W.; Song, H.; Rubakovic, A.; Chang, W.; Medalla, M.; Weaver, C.M.; Luebke, J.I. Differential Changes
506 to D1 and D2 Medium Spiny Neurons in the 12-Month-Old Q175+/- Mouse Model of Huntington's Disease. *PLoS*
507 *One* **2018**, *13*, e0200626, doi:10.1371/journal.pone.0200626.
- 508 28. Megret, L.; Gris, B.; Sasidharan Nair, S.; Cevost, J.; Wertz, M.; Aaronson, J.; Rosinski, J.; Vogt, T.F.; Wilkinson, H.;
509 Heiman, M.; et al. Shape Deformation Analysis Reveals the Temporal Dynamics of Cell-Type-Specific
510 Homeostatic and Pathogenic Responses to Mutant Huntingtin. *Elife* **2021**, *10*, e64984, doi:10.7554/eLife.64984.
- 511 29. Matsushima, A.; Pineda, S.S.; Crittenden, J.R.; Lee, H.; Galani, K.; Mantero, J.; Tombaugh, G.; Kellis, M.; Heiman,
512 M.; Graybiel, A.M. Transcriptional Vulnerabilities of Striatal Neurons in Human and Rodent Models of
513 Huntington's Disease. *Nat Commun* **2023**, *14*, 282, doi:10.1038/s41467-022-35752-x.
- 514 30. Jeon, T.-I.; Osborne, T.F. SREBPs: Metabolic Integrators in Physiology and Metabolism. *Trends Endocrinol Metab*
515 **2012**, *23*, 65–72, doi:10.1016/j.tem.2011.10.004.
- 516 31. Birolini, G.; Verlengia, G.; Talpo, F.; Maniezzi, C.; Zentilin, L.; Giacca, M.; Conforti, P.; Cordiglieri, C.; Caccia, C.;
517 Leoni, V.; et al. SREBP2 Gene Therapy Targeting Striatal Astrocytes Ameliorates Huntington's Disease
518 Phenotypes. *Brain* **2021**, doi:10.1093/brain/awab186.
- 519 32. Zhou, X.; Fu, A.K.; Ip, N.Y. APOE Signaling in Neurodegenerative Diseases: An Integrative Approach Targeting
520 APOE Coding and Noncoding Variants for Disease Intervention. *Curr Opin Neurobiol* **2021**, *69*, 58–67,
521 doi:10.1016/j.conb.2021.02.001.
- 522 33. Valenza, M.; Leoni, V.; Karasinska, J.M.; Petricca, L.; Fan, J.; Carroll, J.; Pouladi, M.A.; Fossale, E.; Nguyen, H.P.;
523 Riess, O.; et al. Cholesterol Defect Is Marked across Multiple Rodent Models of Huntington's Disease and Is
524 Manifest in Astrocytes. *J Neurosci* **2010**, *30*, 10844–10850, doi:10.1523/JNEUROSCI.0917-10.2010.
- 525 34. Pikuleva, I.A.; Cartier, N. Cholesterol Hydroxylating Cytochrome P450 46A1: From Mechanisms of Action to
526 Clinical Applications. *Front Aging Neurosci* **2021**, *13*, 696778, doi:10.3389/fnagi.2021.696778.
- 527 35. Wang, F.; Flanagan, J.; Su, N.; Wang, L.-C.; Bui, S.; Nielson, A.; Wu, X.; Vo, H.-T.; Ma, X.-J.; Luo, Y. RNAscope: A
528 Novel in Situ RNA Analysis Platform for Formalin-Fixed, Paraffin-Embedded Tissues. *J Mol Diagn* **2012**, *14*, 22–29,
529 doi:10.1016/j.jmoldx.2011.08.002.
- 530 36. Lee, H.; Fenster, R.J.; Pineda, S.S.; Gibbs, W.S.; Mohammadi, S.; Davila-Velderrain, J.; Garcia, F.J.; Therrien, M.;
531 Novis, H.S.; Gao, F.; et al. Cell Type-Specific Transcriptomics Reveals That Mutant Huntingtin Leads to
532 Mitochondrial RNA Release and Neuronal Innate Immune Activation. *Neuron* **2020**, *107*, 891–908.e8,
533 doi:10.1016/j.neuron.2020.06.021.
- 534 37. Benraiss, A.; Mariani, J.N.; Osipovitch, M.; Cornwell, A.; Windrem, M.S.; Villanueva, C.B.; Chandler-Militello, D.;
535 Goldman, S.A. Cell-Intrinsic Glial Pathology Is Conserved across Human and Murine Models of Huntington's
536 Disease. *Cell Reports* **2021**, *36*, 109308, doi:10.1016/j.celrep.2021.109308.
- 537 38. Gangwani, M.R.; Soto, J.S.; Jami-Alahmadi, Y.; Tiwari, S.; Kawaguchi, R.; Wohlschlegel, J.A.; Khakh, B.S.
538 Neuronal and Astrocytic Contributions to Huntington's Disease Dissected with Zinc Finger Protein
539 Transcriptional Repressors. *Cell Rep* **2023**, *42*, 111953, doi:10.1016/j.celrep.2022.111953.

-
- 540 39. Boyles, J.K.; Pitas, R.E.; Wilson, E.; Mahley, R.W.; Taylor, J.M. Apolipoprotein E Associated with Astrocytic Glia
541 of the Central Nervous System and with Nonmyelinating Glia of the Peripheral Nervous System. *J Clin Invest*
542 **1985**, *76*, 1501–1513, doi:10.1172/JCI112130.
- 543 40. Pitas, R.E.; Boyles, J.K.; Lee, S.H.; Foss, D.; Mahley, R.W. Astrocytes Synthesize Apolipoprotein E and Metabolize
544 Apolipoprotein E-Containing Lipoproteins. *Biochim Biophys Acta* **1987**, *917*, 148–161,
545 doi:10.1016/0005-2760(87)90295-5.

546